Omnes Capital's exits: Fovea Pharmaceuticals

Sector 
Pharma
Entry Date 
10/2005
Exit Date 
10/2009
Buyer 
Sanofi Aventis
Business 
Venture Capital

Fovea Pharmaceuticals

Ocular franchise dedicated to discovering therapies for retinal conditions

Founded in 2005 to break new ground in the treatment of retinal conditions, Fovea Pharmaceuticals has built an R&D portfolio covering ocular conditions with unmet needs, and now forms Sanofi’s Ophthalmology division. Its core approach is to put patients at the heart of its strategy, thanks to its presence at the Institut de la Vision located on the Quinze-Vingts hospital campus. Its team consists almost exclusively of research scientists. 
The company was bought by Sanofi Aventis in 2009 in a deal worth up to €370 million.